Less Ads, More Data, More Tools Register for FREE

Pin to quick picksargenx Share Price (ARGX.BR)

Share Price Information for argenx (ARGX.BR)

Share Price is delayed by 15 minutes
Get Live Data
786.00    12.20 (1.577%)
Bid:
785.60
Ask:
786.20
Spread: 0.60 (0.076%)
Market Cap: €48.88b
ARGX.BR Live PriceLast checked at - Euronext Brussels

Intraday argenx Share Chart

  • This share is an international stock.
argenx Share Price
Price 786.00 Open 779.40
Bid 785.60 High 792.00
Ask 786.20 Low 777.00
Change 12.20 (1.577%) Close 773.80
Volume 7,740
Currency EUR
Issue Country NLD
Shares in Issue 62.19m
Market Cap €48.88b
PE Ratio 51.9841
EPS 15.12
Year High 810.00
Year High Date -
Year Low 456.60
Year Low Date -
Dividend 0.00
Yield 0.00%
# Trades 971
Vol. Sold 6,732
Sold Value €1.04m
Vol. Bought 1,008
Bought Value €792.62k
Market Size 10,000
What if I invested €1,000 in argenx?
€ 1,121.26 (+12.13%)
1 month ago
€ 1,344.05 (+34.40%)
3 months ago
€ 1,082.64 (+8.26%)
6 months ago
€ 1,668.44 (+66.84%)
1 year ago
Add ARGX.BR to WatchlistAdd ARGX.BR to Watchlist

Compare Broker Offers

Selected partners may offer promotions for new customers. We may earn a referral fee if you open an account

Great for:
Active Traders
View Offer
Capital at risk
Great for:
Copy Trading
View Offer
Other fees apply.
Capital at risk.
Great for:
ISAs & SIPPs
View Offer
Capital at risk
Great for:
Beginner Friendly
View Offer
Capital at risk
Argenx Se

argenx is listed in the Medicine and Biotech sector.

Argenx Se is listed on the Euronext Brussels trading with ticker code ARGX.BR. It has a market capitalisation of €48.88b, with approximately 62.19m shares in issue. Over the last year, argenx share price has been traded in a range of 353.40, hitting a high of 810.00, and a low of 456.60. It is classified as being part of the Biotechnology subsector.

argenx SE is a biopharmaceutical company headquartered in Belgium, specialising in the discovery and development of innovative antibody-based therapies for severe autoimmune diseases and cancer. Leveraging its proprietary antibody platform, the company aims to address unmet medical needs and improve patient outcomes. argenx's pipeline includes promising candidates targeting various diseases, including myasthenia gravis and acute myeloid leukemia. Committed to scientific excellence and patient-centric innovation, argenx collaborates with leading researchers and institutions to advance its therapeutic programs. With a focus on transformative treatments, the company continues to make significant strides in the field of biotechnology.

Recent Share Trades for argenx (ARGX.BR)

Date Time Trade Prc Volume Buy/Sell Bid Ask Value  
22-Jun-2610:18:57786.007Unknown*785.40786.205,502A Automatic Execution
22-Jun-2610:18:57786.0013Sell*785.40786.2010.22kA Automatic Execution
22-Jun-2610:18:49785.8018Unknown*785.40786.2014.14kA Automatic Execution
22-Jun-2610:18:49785.808Unknown*785.80786.206,286A Automatic Execution
22-Jun-2610:18:47785.802Buy*785.80786.201,572A Automatic Execution
22-Jun-2610:18:33786.201Unknown*785.80786.20786.20A Automatic Execution
22-Jun-2610:18:33786.201Unknown*785.80786.20786.20A Automatic Execution
22-Jun-2610:18:33786.201Unknown*785.80786.20786.20A Automatic Execution
22-Jun-2610:18:33786.202Sell*785.80786.201,572A Automatic Execution
22-Jun-2610:18:32785.8019Unknown*785.60786.4014.93kA Automatic Execution
  • There are no chat posts for argenx
argenx

The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.

argenx Home Page